Sagimet Biosciences Inc.
SGMTNasdaq
$7.82
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↓ -18.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$254.6M
Enterprise Value
$150.1M
P/E
—
P/S
—
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$43.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-42.5%
ROIC
—
Debt / Equity
—
Net Cash
$104.5M
Return 1Y
-18.1%
Company profile
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. We were incorporated in Delaware in December 2006 under the name 3-V Biosciences, Inc., and changed our name to Sagimet Biosciences Inc. in August 2019. Our principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California.
- CEO
- David Happel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.sagimet.com
Management & directors
- Chauche ThierryChief Financial Officer
- Happel DavidPresident & CEO
- Martins Eduardo BrunoChief Medical Officer
- Rozek ElizabethChief Legal & Admin. Officer
- Kemble GeorgeExecutive Chairman
Roles derived from SEC Form 4 filings.
Earnings
SGMT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.33↓ -41.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $2.0M | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$31.1M | -$30.7M | -$54.5M | -$56.9M |
| Net income | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| Diluted EPS | -$165.20 | -$2.66 | -$1.45 | -$1.58 |
| Operating cash flow | -$24.5M | -$23.8M | -$42.4M | -$45.6M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | -1537.0% | — | — |
| Net margin | — | -1393.8% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.6M | -$16.9M | -$18.2M | -$19.9M | -$11.9M | -$14.3M | -$10.8M | -$11.7M |
| Net income | -$8.1M | -$14.6M | -$16.2M | -$18.2M | -$10.4M | -$12.9M | -$9.6M | -$10.7M |
| Diluted EPS | -$0.25 | -$0.45 | -$0.52 | -$0.56 | -$0.32 | -$0.40 | -$0.30 | -$0.33 |
| Operating cash flow | -$5.6M | -$19.6M | -$11.0M | -$14.5M | -$9.1M | -$10.2M | -$11.8M | -$8.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-19 | Rozek Elizabeth· Chief Legal & Admin. Officer | Award | 44,000 | $0.00 | $0.00 | filing |
| 2026-02-19 | Martins Eduardo Bruno· Chief Medical Officer | Award | 44,000 | $0.00 | $0.00 | filing |
| 2026-02-19 | Happel David· President & CEO | Award | 128,000 | $0.00 | $0.00 | filing |
| 2026-02-19 | Chauche Thierry· Chief Financial Officer | Award | 44,000 | $0.00 | $0.00 | filing |
| 2026-02-10 | Happel David· President & CEO | Sale | 12,101 | $5.36 | $64,864.99 | filing |
| 2026-02-10 | Martins Eduardo Bruno· Chief Medical Officer | Sale | 3,640 | $5.36 | $19,511.13 | filing |
| 2026-02-10 | Rozek Elizabeth· Chief Legal & Admin. Officer | Sale | 2,622 | $5.36 | $14,054.44 | filing |
| 2026-02-10 | Chauche Thierry· Chief Financial Officer | Sale | 1,312 | $5.36 | $7,032.71 | filing |
| 2025-11-20 | Kemble George· Executive Chairman | Sale | 37,688 | $7.69 | $289,979.01 | filing |
| 2025-11-04 | Rozek Elizabeth· Chief Legal & Admin. Officer | Award | 9,855 | $0.00 | $0.00 | filing |
| 2025-07-21 | Happel David· President & CEO | Sale | 65,478 | $9.13 | $598,115.34 | filing |
| 2025-07-21 | Rozek Elizabeth· General Counsel and CCO | Sale | 10,780 | $9.13 | $98,470.99 | filing |
| 2025-07-21 | Martins Eduardo Bruno· Chief Medical Officer | Sale | 8,277 | $9.13 | $75,607.08 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.